Effectiveness and safety of @entity7978 @entity229 in XXXX : a retrospective cohort study of 103 @entity1 .

@entity1 @entity1667 @entity7978 @entity229 @entity226 @entity2101 @entity1499 @entity792
OBJECTIVES: To compare the effectiveness and safety of @entity7978 ( @entity7978 ) and @entity2101 ( @entity2101 ) @entity229 regimens and to identify factors related to remission with a target maintenance dose of @entity229 in @entity1 with @entity226 ( @entity226 ). METHODS: Retrospective cohort study conducted in an @entity792 unit. @entity1 received  <= 30 mg ( @entity7978 group) or >30 mg ( @entity2101 group) of daily @entity229 as monotherapy or combined with @entity1667 pulses and/or @entity1499 , at the discretion of the physician. The primary endpoint was time to clinical and biological remission receiving a @entity229 maintenance dose  <= 7.5 mg/day. Factors related to the primary endpoint were identified by Cox regression analysis. RESULTS: Overall, 103 @entity1 ( @entity7978 =53, @entity2101 =50) were followed for a median (95%CI) of 2.85 (2.57-3.52) years. Both groups exhibited similar baseline features except for ocular ischaemic manifestations ( @entity7978 =21%, @entity2101 =48%, p=0.004). @entity1 in the @entity7978 group had a shorter time to the primary endpoint ( @entity7978 =186 [147-223], @entity2101 =236 [177-276] days, HR=1.70 [1.12-2.57], p=0.01) with no increase in relapses ( @entity7978 =39%, @entity2101 =50%, p=0.29) or @entity226 ( @entity7978 =11%, @entity2101 =16%, p=0.49). Cumulative @entity229 doses at 6 months were 2.47    0.70 g for @entity7978 @entity1 and 3.86    1.85 g for @entity2101 @entity1 (p<0.001). Adverse effects were more frequent among @entity2101 recipients ( @entity7978 =43%, @entity2101 =66%, p=0.02). The only independent factor associated with the primary endpoint was the use of @entity1667 pulses (HR=2.21 [1.31-3.71], p=0.003). CONCLUSIONS: @entity7978 @entity229 regimen may be an effective and safe alternative to @entity2101 @entity229 regimen in @entity226 . Induction with @entity1667 pulses predicts a better response, allowing for a less intensive @entity229 regimen.
